Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
SpringWorks Therapeutics Inc is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. SpringWorks Therapeutics employs 110 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$61.12|
|52-week range||$51.57 - $96.48|
|50-day moving average||$69.50|
|200-day moving average||$75.33|
|Wall St. target price||$114.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.87|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||11.55%|
|1 month (2021-09-17)||-18.29%|
|3 months (2021-07-17)||-25.60%|
|6 months (2021-04-16)||-12.70%|
|1 year (2020-10-16)||3.37%|
|2 years (2019-10-17)||210.25%|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
|Revenue TTM||$35 million|
|Gross profit TTM||$35 million|
|Return on assets TTM||-13.26%|
|Return on equity TTM||-22.14%|
|Market capitalisation||$2.7 billion|
TTM: trailing 12 months
There are currently 3.1 million SpringWorks Therapeutics shares held short by investors – that's known as SpringWorks Therapeutics's "short interest". This figure is 4.2% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting SpringWorks Therapeutics shares can be evaluated.
SpringWorks Therapeutics's "short interest ratio" (SIR) is the quantity of SpringWorks Therapeutics shares currently shorted divided by the average quantity of SpringWorks Therapeutics shares traded daily (recently around 230525.47864507). SpringWorks Therapeutics's SIR currently stands at 13.58. In other words for every 100,000 SpringWorks Therapeutics shares traded daily on the market, roughly 13580 shares are currently held short.
However SpringWorks Therapeutics's short interest can also be evaluated against the total number of SpringWorks Therapeutics shares, or, against the total number of tradable SpringWorks Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SpringWorks Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 SpringWorks Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1173% of the tradable shares (for every 100,000 tradable SpringWorks Therapeutics shares, roughly 117 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against SpringWorks Therapeutics.
Find out more about how you can short SpringWorks Therapeutics stock.
We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, SpringWorks Therapeutics's shares have ranged in value from as little as $51.57 up to $96.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SpringWorks Therapeutics's is 0.8246. This would suggest that SpringWorks Therapeutics's shares are less volatile than average (for this exchange).
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd. , GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.